New hope in therapy of ovarian cancer;Neue hoffnungsträger in der therapie des ovarialkarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 64, Issue 8, 2004, Pages 777-780

  Wagner, U ^a,e   Pfisterer, J ^b   Jackisch, C ^a   Meier, W ^c   Du Bois, A ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Children s Hospital   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e Gyn Endokrinologie u Onkologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; ERLOTINIB; ERYTHROPOIETIN; GEFITINIB; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; THALIDOMIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; DRUG INDICATION; EDITORIAL; FEMALE; HUMAN; OVARY CANCER; OVARY CARCINOMA;

EID: 4344574972     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821088     Document Type: Editorial

References (10)

1. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics 1999. CA Cancer J Clinicians 1999; 49: 8-31
2. du Bois A, Lück H, Meier W, Adams H, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1330
3. Ozols R. Future directions in the treatment of ovarian cancer. Semin Oncol 2002; 29: 32-42
4. Muggia F, Brady M, Alvarez R. Maintenance chemotherapy in advanced ovarian Cancer. J Clin Oncol 2000; 18: 1804
5. Green M. Targeting targeted therapy. N Engl J Med 2004; 21: 348
6. Baselga J, Rischin D, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Averbuch S, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302
7. Adjei A, Davis J, Bruzek L, Erlichrnann C, Kaufmann S. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Can Res 2001; 7: 1438-1445
8. Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 1998; 83: 726-731
9. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack H, Möbus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment. Clin Can Res 2001; 7: 1154-1162
10. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (Ep-CAM) and CD3. J Immunol 1997; 158: 3965-3970